Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 83
Inquire Before Buying

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H2 2018, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the esophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastro esophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 5, 3 and 1 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Overview
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co Ltd
Chong Kun Dang Pharmaceutical Corp
CJ HealthCare Corp
Daewoong Pharmaceutical Co Ltd
Eisai Co Ltd
Ilyang Pharmaceutical Co Ltd
Ironwood Pharmaceuticals Inc
Jeil Pharmaceutical Co Ltd
RaQualia Pharma Inc
Sun Pharma Advanced Research Company Ltd
Takeda Pharmaceutical Co Ltd
Yooyoung Pharm Co Ltd
Yuyu Pharma Inc
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Drug Profiles
(esomeprazole + sodium bicarbonate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
azeloprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ceclazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-30065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colesevelam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexlansoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWP-14012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ilaprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 for Peptic Ulcers and Reflux Esophagitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vonoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
X-842 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-DXR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Product Development Milestones
Featured News & Press Releases
Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastro esophageal Reflux Disease (GERD) at Digestive Disease Week 2018
Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD
Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastro esophageal Reflux Disease
Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastro esophageal Reflux Disease
Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
Jan 27, 2016: FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)
Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
Feb 26, 2015: TAKECAB Now Available for the Treatment of Acid-related Diseases in Japan
Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastro esophageal Reflux Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by CJ HealthCare Corp, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H2 2018 (Contd..1), H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H2 2018
Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures
Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global Short Bowel Syndrome (SBS) Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 24-Sep-2018        Price: US 3480 Onwards        Pages: 118
    Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Scope of the Report: This report studies the Short Bowel Syndrome (SBS) market status and outlook of Global and major regions, from angles of ......
  • 2018-2023 Global Irritable Bowel Syndrome (IBS) Consumption Market Report
    Published: 20-Sep-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Irritable Bowel Syndrome (IBS) market for 2018-2023. Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IB......
  • 2015-2023 World Drugs for Traveler's Diarrhea Market Research Report by Product Type, End-User / Application and Regions / Countries
    Published: 12-Sep-2018        Price: US 2800 Onwards        Pages: 97
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. Market Segment as follows: By Region / Countries - North America (U.S., Canada, Mexico) - Europe (Germany, U.K., France, Italy, Russia, Spain etc) - South America (Brazil, Argentina etc)......
  • Gastric Ulcers - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 44
    Gastric Ulcers - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Ulcers - Pipeline Review, H2 2018, provides an overview of the Gastric Ulcers (Gastrointestinal) pipeline landscape. Gastric ulcer is a painful sore or ulcer in the lining of stomach. The most common cause of gastric ulcer is Helicobacter pylori bacterial infection. Symptoms include pain, bloating, retching, nausea or......
  • Celiac Disease - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 85
    Celiac Disease - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2018, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk fa......
  • Pancreatitis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 87
    Pancreatitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2018, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape. Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors inclu......
  • Alcoholic Hepatitis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 76
    Alcoholic Hepatitis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2018, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape. Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, w......
  • Global Gastrointestinal OTC Drugs Market Insights, Forecast to 2025
    Published: 07-Sep-2018        Price: US 3900 Onwards        Pages: 124
    This report studies the global market size of Gastrointestinal OTC Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Gastrointestinal OTC Drugs in these regions. This research report categorizes the global Gastrointestinal OTC Drugs market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future tre......
  • Digital Landscape: Inflammatory Bowel Disease
    Published: 06-Sep-2018        Price: US 6000 Onwards        Pages: 159
    Digital Landscape: Inflammatory Bowel Disease Summary The Digital Landscape Inflammatory Bowel Disease report analyzes digital activities undertaken by pharma in support of disease-modifying therapies for mild-to-moderate, and moderate-to-severe Crohn's disease and ulcerative colitis (UC). Key Highlights - US Patients: AbbVie offers the strongest support for IBD patients in the US, particularly branded, unbranded and mobile app. Janssen......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs